Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities
Hydrogen sulfide (H2S), a gas transmitter found in eukaryotic organisms, plays an essential role in several physiological processes. H2S is one of the three primary biological gas transmission signaling mediators, along with nitric oxide and carbon monoxide. Several animal and in vitro experiments h...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.909178/full |
| _version_ | 1811216459943116800 |
|---|---|
| author | Ye-Wei Yang Nian-Hua Deng Kai-Jiang Tian Lu-Shan Liu Zuo Wang Dang-Heng Wei Hui-Ting Liu Zhi-Sheng Jiang |
| author_facet | Ye-Wei Yang Nian-Hua Deng Kai-Jiang Tian Lu-Shan Liu Zuo Wang Dang-Heng Wei Hui-Ting Liu Zhi-Sheng Jiang |
| author_sort | Ye-Wei Yang |
| collection | DOAJ |
| description | Hydrogen sulfide (H2S), a gas transmitter found in eukaryotic organisms, plays an essential role in several physiological processes. H2S is one of the three primary biological gas transmission signaling mediators, along with nitric oxide and carbon monoxide. Several animal and in vitro experiments have indicated that H2S can prevent coronary endothelial mesenchymal transition, reduce the expression of endothelial cell adhesion molecules, and stabilize intravascular plaques, suggesting its potential role in the treatment of atherosclerosis (AS). H2S donors are compounds that can release H2S under certain circumstances. Development of highly targeted H2S donors is a key imperative as these can allow for in-depth evaluation of the anti-atherosclerotic effects of exogenous H2S. More importantly, identification of an optimal H2S donor is critical for the creation of H2S anti-atherosclerotic prodrugs. In this review, we discuss a wide range of H2S donors with anti-AS potential along with their respective transport pathways and design-related limitations. We also discuss the utilization of nano-synthetic technologies to manufacture H2S donors. This innovative and effective design example sheds new light on the production of highly targeted H2S donors. |
| first_indexed | 2024-04-12T06:39:26Z |
| format | Article |
| id | doaj.art-b85ca2d0a4204be79575c59e9efa40af |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T06:39:26Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-b85ca2d0a4204be79575c59e9efa40af2022-12-22T03:43:45ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-08-01910.3389/fcvm.2022.909178909178Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future prioritiesYe-Wei Yang0Nian-Hua Deng1Kai-Jiang Tian2Lu-Shan Liu3Zuo Wang4Dang-Heng Wei5Hui-Ting Liu6Zhi-Sheng Jiang7Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaKey Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, Institute of Cardiovascular Disease, University of South China, Hengyang, ChinaHydrogen sulfide (H2S), a gas transmitter found in eukaryotic organisms, plays an essential role in several physiological processes. H2S is one of the three primary biological gas transmission signaling mediators, along with nitric oxide and carbon monoxide. Several animal and in vitro experiments have indicated that H2S can prevent coronary endothelial mesenchymal transition, reduce the expression of endothelial cell adhesion molecules, and stabilize intravascular plaques, suggesting its potential role in the treatment of atherosclerosis (AS). H2S donors are compounds that can release H2S under certain circumstances. Development of highly targeted H2S donors is a key imperative as these can allow for in-depth evaluation of the anti-atherosclerotic effects of exogenous H2S. More importantly, identification of an optimal H2S donor is critical for the creation of H2S anti-atherosclerotic prodrugs. In this review, we discuss a wide range of H2S donors with anti-AS potential along with their respective transport pathways and design-related limitations. We also discuss the utilization of nano-synthetic technologies to manufacture H2S donors. This innovative and effective design example sheds new light on the production of highly targeted H2S donors.https://www.frontiersin.org/articles/10.3389/fcvm.2022.909178/fullhydrogen sulfidedonoratheroscleroticnanotechnologydrug delivery and targeting |
| spellingShingle | Ye-Wei Yang Nian-Hua Deng Kai-Jiang Tian Lu-Shan Liu Zuo Wang Dang-Heng Wei Hui-Ting Liu Zhi-Sheng Jiang Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities Frontiers in Cardiovascular Medicine hydrogen sulfide donor atherosclerotic nanotechnology drug delivery and targeting |
| title | Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities |
| title_full | Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities |
| title_fullStr | Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities |
| title_full_unstemmed | Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities |
| title_short | Development of hydrogen sulfide donors for anti-atherosclerosis therapeutics research: Challenges and future priorities |
| title_sort | development of hydrogen sulfide donors for anti atherosclerosis therapeutics research challenges and future priorities |
| topic | hydrogen sulfide donor atherosclerotic nanotechnology drug delivery and targeting |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.909178/full |
| work_keys_str_mv | AT yeweiyang developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT nianhuadeng developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT kaijiangtian developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT lushanliu developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT zuowang developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT danghengwei developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT huitingliu developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities AT zhishengjiang developmentofhydrogensulfidedonorsforantiatherosclerosistherapeuticsresearchchallengesandfuturepriorities |